Roles of the hepcidin–ferroportin axis and iron in cancer
Roles of the hepcidin–ferroportin axis and iron in cancer
复制标题
DOI：
10.1097/cej.0b013e3283627f14
复制
发表时间：
2014-03
影响因子：
2.4
通讯作者：
Xian-Ning Wu;Dan Su;Li Wang;F. Yu
中科院分区：
文献类型：
--
作者：
Xian-Ning Wu;Dan Su;Li Wang;F. Yu
铁调素是一种低分子量的肝肽，其调节铁稳态，并通过引起其受体（细胞铁输出体膜铁转运蛋白）的降解而起作用。基于铁调素-铁转运蛋白轴在铁调节中的主要作用，最近一些研究讨论了其表达及其对癌症发展和预后的影响。铁在体内平衡中起着关键作用。然而，对正常铁调节机制的深入了解为癌症铁代谢变化的基本机制、生物学原理和病理生理学意义提供了新的视角。除了是癌症的重要刺激因素外，铁功能障碍还导致癌症相关性贫血。在这篇综述中，我们讨论了铁调素-铁转运蛋白轴和铁的调节方面，以及它们在癌症中的内在联系。我们还试图考虑进一步个体化治疗的新靶点的理论可能性。然而，这些调节剂的许多分子机制和功能仍不清楚。
Hepcidin is a low-molecular-weight hepatic peptide that regulates iron homeostasis, and acts by causing the degradation of its receptor, the cellular iron exporter ferroportin. On the basis of the major role of the hepcidin–ferroportin axis in iron regulation, recently several studies have discussed its expression and influence on the development and prognosis of cancer. Iron plays a pivotal role in homeostasis. However, insights into the mechanisms of normal iron regulation have provided a new perspective on the basic mechanisms, biological rationale, and pathophysiologic implications of changes in iron metabolism in cancer. Besides being a crucial stimulus for cancer, iron dysfunction also causes cancer-related anemia. In this review, we discuss aspects of the hepcidin–ferroportin axis and iron regulation, as well as the inherent connections between them in cancer. We also attempt to consider the possibility in theory of novel targets for further individualized therapy. However, many molecular mechanisms and functions of these regulators remain unclear.